Affordable Access

deepdyve-link
Publisher Website

Does asymptomatic bacteriuria increase the risk of adverse events or modify the efficacy of intradetrusor onabotulinumtoxinA injections?

Authors
  • Aharony, Shachar1
  • Przydacz, Mikolaj1, 2
  • Van Ba, Ornella L1
  • Corcos, Jacques1
  • 1 Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. , (Canada)
  • 2 Department of Urology, Jagiellonian University Medical College, Krakow, Poland. , (Poland)
Type
Published Article
Journal
Neurourology and Urodynamics
Publisher
Wiley (John Wiley & Sons)
Publication Date
Oct 02, 2019
Identifiers
DOI: 10.1002/nau.24169
PMID: 31578763
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To assess the impact of asymptomatic bacteriuria (ASB) on the safety and efficacy of intradetrusor onabotulinumtoxinA injections in patients with overactive bladder and neurogenic detrusor overactivity. We reviewed the medical records of patients who had received onabotulinumtoxinA between 2009 and 2014. Safety analysis was based on the appearance of urinary tract infections (UTIs), hematuria, and need for hospitalization because of related adverse event(s) in the month after injection. Patients who underwent urodynamic study before and 3 months after the first onabotulinumtoxinA treatment were included in efficacy analysis. Changes in maximal cystometric capacity (MCC), bladder compliance (BC), maximal detrusor pressure at maximal involuntary detrusor contraction (Pdetmax), and detrusor leak point pressure (DLPP) were assessed. Totally, 183 patients underwent 457 injection sessions. ASB was found in 38.8% (185) of urine cultures taken before injections. After treatment, 49 patients (with or without ASB) developed UTI. Urosepsis did not occur. The odds ratio of UTI in patients with ASB was 16.48. The efficacy cohort, consisting of 83 patients, showed that ASB had no significant effect on any of the efficacy parameters (MCC-risk ratio [RR]: 0.93, 95% confidence interval [CI]: 0.72-1.21; BC-RR: 0.88, 95% CI: 0.62-1.24; Pdetmax-RR: 0.9, 95% CI: 0.69-1.21; DLPP-RR: 1.69, 95% CI: 0.72-3.97). ASB is common among patients who are candidates for intradetrusor onabotulinumtoxinA treatment. ASB increases the risk of UTI, but does not heighten the risk of urosepsis, hospitalization, or therapy failure. This study should lead to the reconsideration of current recommendations. © 2019 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times